Renaissance Technologies’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-45,100
| Closed | -$3.25M | – | 3615 |
|
|
2025
Q4 | $3.25M | Buy |
+45,100
| New | +$2.91M | 0.01% | 1593 |
|
|
2025
Q1 | – | Sell |
-211,200
| Closed | -$6.14M | – | 3775 |
|
|
2024
Q4 | $6.14M | Buy |
211,200
+69,300
| +49% | +$2.9M | 0.01% | 1319 |
|
|
2024
Q3 | $6.52M | Sell |
141,900
-235,500
| -62% | -$10.2M | 0.01% | 1282 |
|
|
2024
Q2 | $15.4M | Buy |
+377,400
| New | +$10.8M | 0.03% | 708 |
|
|
2024
Q1 | – | Sell |
-226,700
| Closed | -$2.05M | – | 4006 |
|
|
2023
Q4 | $2.05M | Buy |
226,700
+115,900
| +105% | +$775K | ﹤0.01% | 1934 |
|
|
2023
Q3 | $707K | Buy |
110,800
+44,900
| +68% | +$387K | ﹤0.01% | 2535 |
|
|
2023
Q2 | $731K | Sell |
65,900
-309,200
| -82% | -$3.88M | ﹤0.01% | 2670 |
|
|
2023
Q1 | $5.76M | Buy |
375,100
+208,500
| +125% | +$4.59M | 0.01% | 1392 |
|
|
2022
Q4 | $3.7M | Buy |
166,600
+42,600
| +34% | +$635K | 0.01% | 1694 |
|
|
2022
Q3 | $2.02M | Buy |
124,000
+15,700
| +14% | +$300K | ﹤0.01% | 1996 |
|
|
2022
Q2 | $1.57M | Buy |
108,300
+69,900
| +182% | +$1.04M | ﹤0.01% | 2369 |
|
|
2022
Q1 | $709K | Buy |
38,400
+26,800
| +231% | +$455K | ﹤0.01% | 2962 |
|
|
2021
Q4 | $276K | Buy |
+11,600
| New | +$277K | ﹤0.01% | 3377 |
|
Other funds holding RNAM
Renaissance Technologies's RNAM Position: Q1 2026 in Review
Renaissance Technologies sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 45,100 shares — an estimated $3.25M sold.
Renaissance Technologies first reported a position in RNAM in Q4 2021 and held it in 13 quarters. The position peaked at $15.4M in Q2 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Renaissance Technologies reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Renaissance Technologies sold 45,100 Avidity Biosciences shares in Q1 2026, an estimated $3.25M.
- Renaissance Technologies first reported a position in Avidity Biosciences in Q4 2021 and held it in 13 quarters.
- Renaissance Technologies's Avidity Biosciences position peaked at $15.4M in Q2 2024.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.